Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,140 shares of the biopharmaceutical company’s stock after selling 854 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Gilead Sciences were worth $382,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Savant Capital LLC boosted its holdings in Gilead Sciences by 2.0% in the fourth quarter. Savant Capital LLC now owns 27,921 shares of the biopharmaceutical company’s stock valued at $2,579,000 after acquiring an additional 558 shares during the last quarter. Wagner Wealth Management LLC boosted its holdings in Gilead Sciences by 8.5% in the fourth quarter. Wagner Wealth Management LLC now owns 8,710 shares of the biopharmaceutical company’s stock valued at $805,000 after acquiring an additional 684 shares during the last quarter. Angeles Wealth Management LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $200,000. Stone Summit Wealth LLC boosted its holdings in Gilead Sciences by 6.3% in the fourth quarter. Stone Summit Wealth LLC now owns 30,503 shares of the biopharmaceutical company’s stock valued at $2,818,000 after acquiring an additional 1,798 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock worth $53,611,715 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research reports. Wells Fargo & Company raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Barclays raised their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group raised their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Stock Down 0.6 %

Shares of Gilead Sciences stock opened at $95.48 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $118.99 billion, a P/E ratio of 1,060.89, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51. The business has a 50-day moving average price of $93.04 and a 200 day moving average price of $86.86.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.